In addition , 19 letters to the editor/ review s/editorials/experts ' surveys/experts ' opinion were used for discussion purpose s. Conclusions NVAF is highly prevalent among ICH survivors .
The risks of IS , recurrent ICH , and mortality are heightened in this group .
Most published data show a net benefit in terms of IS prevention and mortality when anticoagulation is restarted .
Background We summarize the existing evidence on the potential benefit of oral anticoagulation ( OAC ) in intracerebral hemorrhage ( ICH ) survivors with nonvalvular atrial fibrillation ( NVAF ) .
Antiplatelet use after intracerebral hemorrhage
Background : Survivors of intracerebral hemorrhage are at risk for recurrent intracerebral hemorrhage  and ischemic cardiovascular and cerebrovascular disease . Objective : To determine whether antiplatelet therapy increases the risk of recurrent intracerebral hemorrhage . Methods : The authors review ed data from consecutive survivors of primary intracerebral hemorrhage enrolled in a single-center prospect i ve cohort study . Survivors were followed by telephone interview ; recurrent intracerebral hemorrhage and post – index antiplatelet agent use and duration were recorded . Cox proportional hazards models was used with antiplatelet agent exposure as a time-dependent variable to assess the effect of antiplatelet agent use on recurrent intracerebral hemorrhage , stratified by lobar and deep hemispheric location . Results : Recurrent intracerebral hemorrhage was more common in survivors of lobar hemorrhage compared with survivors of deep hemorrhage ( cumulative 2-year rate 22 % vs 4 % ; p = 0.007 ) . Antiplatelet agents were prescribed in 22 % of intracerebral hemorrhage survivors ( 27/127 lobar , 19/80 deep hemispheric ) , most commonly for prevention of ischemic heart disease . Antiplatelet agent use was not associated with intracerebral hemorrhage recurrence in survivors of either lobar hemorrhage ( hazard ratio [ HR ] 0.8 , 95 % CI 0.3 to 2.3 , p = 0.73 ) or of deep hemorrhage ( HR 1.2 , 95 % CI 0.1 to 14.3 , p = 0.88 ) . Conclusion : Antiplatelet agent use is relatively common following intracerebral hemorrhage but did not appear to be associated with a large increased risk of intracerebral hemorrhage recurrence in this observational study
In addition , 19 letters to the editor/ review s/editorials/experts ' surveys/experts ' opinion were used for discussion purpose s. Conclusions NVAF is highly prevalent among ICH survivors .
The risks of IS , recurrent ICH , and mortality are heightened in this group .
Most published data show a net benefit in terms of IS prevention and mortality when anticoagulation is restarted .
Background We summarize the existing evidence on the potential benefit of oral anticoagulation ( OAC ) in intracerebral hemorrhage ( ICH ) survivors with nonvalvular atrial fibrillation ( NVAF ) .